Charles River Laboratories International announced a plasmid DNA contract development and manufacturing organization collaboration with Axovia Therapeutics Ltd. Charles River will manufacture High Quality gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome, a condition with limited treatment options and no cure. “We are committed to supporting Axovia in the pursuit of creating treatment options for patients living with ciliopathies. The Charles River team brings decades of expertise in HQ plasmid development, and we look forward to using these capabilities to make a difference for patients.” – Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River to perform plasmid production for Ship of Theseus
- Charles River extends gene therapy manufacturing alliance with NUS Medicine
- Charles River price target raised to $290 from $200 at Argus
- Charles River and Navega announce an AAV9 production program agreement
- Durect, Charles River enter collaboration agreement for ALZET product line
